Ghent University Academic Bibliography

Show Sort by

Your filters: cql: author="Bourgeois, Stefan" or (type exact bookEditor and editor="Bourgeois, Stefan")

Add to list
Sustained off-treatment viral control is associated with high hepatitis B surface antigen seroclearance rates in Caucasian patients with nucleos(t)ide analogue-induced HBeAg seroconversion

Stijn Van Hees, Heng Chi, Bettina Hansen, Stefan Bourgeois, Hans Van Vlierberghe (UGent) , Thomas Serste, Sven Francque, David Wong, Dirk Sprengers, Christophe Moreno, et al.

(2019) JOURNAL OF VIRAL HEPATITIS. 26(6). p.766-769
Add to list
- Journal Article
- A1
- open access
Caucasian ethnicity, but not treatment cessation is associated with HBsAg loss following nucleos(t)ide analogue-induced HBeAg seroconversion

Stijn Van Hees, Heng Chi, Bettina Hansen, Stefan Bourgeois, Hans Van Vlierberghe (UGent) , Thomas Serste, Sven Francque, David Wong, Dirk Sprengers, Christophe Moreno, et al.

(2019) VIRUSES-BASEL. 11(8).
Add to list
Pharmacokinetic interactions between simeprevir and ledipasvir in treatment naive hepatitis C virus genotype 1-Infected patients without cirrhosis treated with a simeprevir-sofosbuvir-ledipasvir regimen

Stefan Bourgeois, Yves Horsmans, Frederik Nevens, Hans Van Vlierberghe (UGent) , Christophe Moreno, Maria Beumont, Leen Vijgen, Veerle van Eygen, Donghan Luo, Vera Hillewaert, et al.

(2017) ANTIMICROBIAL AGENTS AND CHEMOTHERAPY. 61(12).
Add to list
Belgian experience with direct acting antivirals in people who inject drugs

Rob Bielen, Christophe Moreno, Hans Van Vlierberghe (UGent) , Stefan Bourgeois, Jean-Pierre Mulkay, Thomas Vanwolleghem, Wim Verlinden, Christian Brixko, Jochen Decaestecker, Chantal De Galocsy, et al.

(2017) DRUG AND ALCOHOL DEPENDENCE. 177. p.214-220
Add to list
- Journal Article
- A1
- open access
Efficacy, safety and pharmacokinetics of simeprevir and TMC647055/ritonavir with or without ribavirin and JNJ-56914845 in HCV genotype 1 infection

Stefan Bourgeois, Hans Van Vlierberghe (UGent) , Christophe Moreno, Hans Orlent, Frederik Nevens, Keikawus Arastéh, Yves Horsmans, Jörn M Schattenberg, Peter Buggisch, Sven Francque, et al.

(2017) BMC GASTROENTEROLOGY. 17.
Add to list
Achieving WHO recommendations for hepatitis C virus elimination in Belgium

Stefan Bourgeois, Sarah Blach, Christian Brixko, Wim Laleman, Catharina Mathei, Jean-Pierre Mulkay, Homie Razavi, Geert Robaeys, Peter Starkel, Pierre Van Damme, et al.

(2016) ACTA GASTRO-ENTEROLOGICA BELGICA. 79(2). p.222-226
Add to list
- Journal Article
- A1
- open access
Impact of safety-related dose reductions or discontinuations on sustained virologic response in HCV-infected patients : results from the GUARD-C cohort

Graham R. Foster, Carmine Coppola, Moutaz Derbala, Peter Ferenci, Alessandra Orlandini, K. Rajender Reddy, Ludovico Tallarico, Mitchell L. Shiffman, Silke Ahlers, Georgios Bakalos, et al.

(2016) PLOS ONE. 11(3).
Add to list
IL28B polymorphism and the control of hepatitis C virus infection: ready for clinical use ?

Hans Orlent, Hendrik Reynaert, Stefan Bourgeois, Vinciane Dideberg, Michael Adler, Isabelle Colle (UGent) , Stephane De Maeght, Wim Laleman, Peter Michielsen, Christophe Moreno, et al.

(2011) ACTA GASTRO-ENTEROLOGICA BELGICA. 74(2). p.317-322

Academic Bibliography

Sustained off-treatment viral control is associated with high hepatitis B surface antigen seroclearance rates in Caucasian patients with nucleos(t)ide analogue-induced HBeAg seroconversion

Caucasian ethnicity, but not treatment cessation is associated with HBsAg loss following nucleos(t)ide analogue-induced HBeAg seroconversion

Pharmacokinetic interactions between simeprevir and ledipasvir in treatment naive hepatitis C virus genotype 1-Infected patients without cirrhosis treated with a simeprevir-sofosbuvir-ledipasvir regimen

Belgian experience with direct acting antivirals in people who inject drugs

Efficacy, safety and pharmacokinetics of simeprevir and TMC647055/ritonavir with or without ribavirin and JNJ-56914845 in HCV genotype 1 infection

Achieving WHO recommendations for hepatitis C virus elimination in Belgium

Impact of safety-related dose reductions or discontinuations on sustained virologic response in HCV-infected patients : results from the GUARD-C cohort

IL28B polymorphism and the control of hepatitis C virus infection: ready for clinical use ?

Contents

Support

Contact